GBR and Autogenous Bone Chips - Trial NCT03946020
Access comprehensive clinical trial information for NCT03946020 through Pure Global AI's free database. This phase not specified trial is sponsored by Universitaire Ziekenhuizen Leuven and is currently Completed. The study focuses on Bone Resorption. Target enrollment is 14 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Universitaire Ziekenhuizen Leuven
Timeline & Enrollment
N/A
Jun 01, 2013
Feb 01, 2019
Primary Outcome
Horizontal and vertical bone augmentation
Summary
This study will be an open, prospective, split-mouth, randomised controlled clinical trial. A
 total of 14 patients searching for oral implant treatment and where a GBR procedure is
 indicated per implant treatment will be enrolled.
 
 All patients have to fulfill all of the inclusion criteria and none of the exclusion
 criteria. From all patients clinical photos will be taken.
 
 Two sites within a patient will be randomly allocated to the 'autologous bone chips and DBBM
 or 'DBBM particles alone' group.
 
 The study will be 1 year follow-up study comprising 9 visits
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT03946020
Non-Device Trial